American International Group, Inc. Corvus Pharmaceuticals, Inc. Transaction History

American International Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$3.3 - $4.58 $29,181 - $40,500	-8,843 Closed	0 $0
Q1 2019 May 06, 2019	SELL	$3.75 - $4.97 $1,076 - $1,426	-287 Reduced 3.14%	8,843 $36,000
Q4 2018 Feb 13, 2019	SELL	$3.29 - $8.94 $230 - $625	-70 Reduced 0.76%	9,130 $34,000
Q3 2018 Nov 09, 2018	BUY	$8.58 - $11.4 $1,424 - $1,892	166 Added 1.84%	9,200 $79,000
Q2 2018 Aug 08, 2018	BUY	$9.42 - $13.73 $34,354 - $50,073	3,647 Added 67.7%	9,034 $99,000
Q1 2018 May 07, 2018	SELL	$7.48 - $11.53 $2,161 - $3,332	-289 Reduced 5.09%	5,387 $62,000
Q4 2017 Feb 09, 2018	BUY	$9.3 - $16.93 $260 - $474	28 Added 0.5%	5,676 $59,000
Q3 2017 Nov 09, 2017	BUY	$11.3 - $17.23 $63,822 - $97,315	5,648	5,648 $90,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.